See what’s available for your patients

Take advantage of the patient resources below and join GoutRx for additional access, office materials, and educational resources.
Members of GoutRx get easy access to useful tools and clinical information about hyperuricemia in gout and ULORIC.

ULORIC (febuxostat) Savings Icon

The ULORIC Savings Program

With the ULORIC Savings Program, eligible patients have 2 savings options for their prescription:

  • $15 co-pay for a prescription of less than 90 days*
  • $0 co-pay for a 90-day prescription*

Patients can visit ULORIC.com for eligibility and enrollment information.

*Must meet eligibility requirements. Maximum benefit of $75 per any prescription less than 90 days or $225 per 90-day prescription. This offer cannot be used if a patient is a beneficiary of, or any part of his or her prescription is covered by: (1) any federal or state healthcare program (Medicare, Medicaid, TRICARE, etc.), including a state pharmaceutical assistance program, (2) the Medicare Prescription Drug Program (Part D), or if a patient is currently in the coverage gap, or (3) insurance that is paying the entire cost of the prescription.

The ULORIC (febuxostat) Savings Card

Help At Hand

At Takeda, we believe all patients should have access to the medication prescribed by their healthcare providers. We also understand that some patients may have financial situations that make it difficult to pay for their prescriptions. Help At Hand provides assistance for people who have no insurance or who do not have enough insurance and need help getting their Takeda medicines. Visit TakedaHelpAtHand.com to learn more.

GoutSmart

We have a lot of resources for patients, including savings, e‑newsletters, and downloadable materials. When patients sign up for the ULORIC Savings Card, they will automatically be signed up for GoutSmart, a personalized educational series of e‑newsletters that allows them to select topics that most appeal to them.

Helpful links

There is a lot of information out there. Help guide your patients to the educational and support resources they are looking for. ULORIC.com has lots of resources for your patients and helpful links to keep them educated about gout. Tell them about the downloadable resources available as well as the ULORIC Patient Brochure and Doctor Discussion Guide so they can be more prepared for their visit with you.

Download the ULORIC
Patient Brochure

Download the ULORIC (febuxostat) Patient Brochure

Download now

Download the complete ULORIC Prescribing Information

Download now

Download the Doctor
Discussion Guide

Download the Doctor Discussion Guide

Download now

Why ULORIC?

Learn about treatment considerations.

ULORIC Efficacy

ULORIC can help lower serum uric acid to <6 mg/dL in gout patients.1

Join GoutRx

As a member of GoutRx,
you can gain access to
useful programs and tools.

IMPORTANT SAFETY INFORMATION

  • ULORIC is contraindicated in patients being treated with azathioprine or mercaptopurine.
  • An increase in gout flares is frequently observed during initiation of anti-hyperuricemic agents, including ULORIC. If a gout flare occurs during treatment, ULORIC need not be discontinued. Prophylactic therapy (i.e., NSAIDs or colchicine) upon initiation of treatment may be beneficial for up to six months.
  • Cardiovascular Events: In randomized controlled studies, there was a higher rate of cardiovascular thromboembolic events (cardiovascular deaths, non-fatal myocardial infarctions, and non-fatal strokes) in patients treated with ULORIC [0.74 per 100 P-Y (95% CI 0.36-1.37)] than allopurinol [0.60 per 100 P-Y (95% CI 0.16-1.53)]. A causal relationship with ULORIC has not been established. Monitor for signs and symptoms of MI and stroke.
  • Hepatic Effects: Postmarketing reports of hepatic failure, sometimes fatal, have been received. Causality cannot be excluded. During randomized controlled studies, transaminase elevations greater than three times the upper limit of normal (ULN) were observed (AST: 2%, 2%, and ALT: 3%, 2% in ULORIC and allopurinol-treated patients, respectively). No dose-effect relationship for these transaminase elevations was noted.
  • Obtain liver tests before starting treatment with ULORIC. Use caution in patients with liver disease. If liver injury is detected, promptly interrupt ULORIC and assess patient for probable cause, then treat cause if possible, to resolution or stabilization. Do not restart treatment if liver injury is confirmed and no alternate etiology can be found.
  • Adverse reactions occurring in at least 1% of ULORIC-treated patients, and at least 0.5% greater than placebo, are liver function abnormalities, nausea, arthralgia, and rash. Patients should be instructed to inform their healthcare professional if they develop a rash or have any side effect that bothers them or does not go away.

Indication

ULORIC (febuxostat) is a xanthine oxidase (XO) inhibitor indicated for the chronic management of hyperuricemia in patients with gout. ULORIC is not recommended for the treatment of asymptomatic hyperuricemia.

Please see the complete Prescribing Information.

Reference:

  1. ULORIC (febuxostat) prescribing information. Takeda Pharmaceuticals.

Important Safety Information

Expand

IMPORTANT SAFETY INFORMATION

  • ULORIC is contraindicated in patients being treated with azathioprine or mercaptopurine.
  • An increase in gout flares is frequently observed during initiation of anti-hyperuricemic agents, including ULORIC. If a gout flare occurs during treatment, ULORIC need not be discontinued. Prophylactic therapy (i.e., NSAIDs or colchicine) upon initiation of treatment may be beneficial for up to six months.
  • Cardiovascular Events: In randomized controlled studies, there was a higher rate of cardiovascular thromboembolic events (cardiovascular deaths, non-fatal myocardial infarctions, and non-fatal strokes) in patients treated with ULORIC [0.74 per 100 P-Y (95% CI 0.36-1.37)] than allopurinol [0.60 per 100 P-Y (95% CI 0.16-1.53)]. A causal relationship with ULORIC has not been established. Monitor for signs and symptoms of MI and stroke.
  • Hepatic Effects: Postmarketing reports of hepatic failure, sometimes fatal, have been received. Causality cannot be excluded. During randomized controlled studies, transaminase elevations greater than three times the upper limit of normal (ULN) were observed (AST: 2%, 2%, and ALT: 3%, 2% in ULORIC and allopurinol-treated patients, respectively). No dose-effect relationship for these transaminase elevations was noted.
  • Obtain liver tests before starting treatment with ULORIC. Use caution in patients with liver disease. If liver injury is detected, promptly interrupt ULORIC and assess patient for probable cause, then treat cause if possible, to resolution or stabilization. Do not restart treatment if liver injury is confirmed and no alternate etiology can be found.
  • Adverse reactions occurring in at least 1% of ULORIC-treated patients, and at least 0.5% greater than placebo, are liver function abnormalities, nausea, arthralgia, and rash. Patients should be instructed to inform their healthcare professional if they develop a rash or have any side effect that bothers them or does not go away.

Indication

ULORIC (febuxostat) is a xanthine oxidase (XO) inhibitor indicated for the chronic management of hyperuricemia in patients with gout. ULORIC is not recommended for the treatment of asymptomatic hyperuricemia.

Please see the complete Prescribing Information.